Inhibition of natural killer cell cytotoxicity and interferon γ production by the envelope protein of HIV and prevention by vasoactive intestinal peptide

AIDS Research and Human Retroviruses

Volumn 16, Issue 11, 2000, Pages 1067-1073

  Peruzzi, Marta ^a   Azzari, Chiara ^a   Rossi, Maria Elisabetta ^a   De Martino, Maurizio ^a   Vierucci, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENVELOPE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON PRODUCTION; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE;

CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ENVELOPE PROTEIN GP120; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE DEPLETION; RECOMBINANT PROTEINS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0034691652     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050075336     Document Type: Article

References (34)

1. 1. See DM, Khemka P, Sahl L, Bui T, and Tilles JG: The role of natural killer cells in viral infections. Scand J Immunol 1997;46: 217-224.
2. 2. Orange JS, Wang B, Terhorst C, and Biron A: Requirement for natural killer cell-produced Interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 1995; 182:1045-1046.
3. 3. Biron CA: Role of early cytokines including alpha and beta interferon (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-390.
4. 4. Brutkiewicz RR and Welsh RM: Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol 1995;69:3967-3971.
5. 5. Bonavida B, Katz J, and Gottlieb M: Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells and partial restoration by IL-2. J Immunol 1986;137:1157-1163.
6. 6. Katz JD, Mitsuyasu MS, Gottlieb MS, Lebow LT, and Bonavida B: Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytoxicity. J Immunol 1987;139:55-60.
7. 7. Margolick JB, Scott ER, Odaka N, and Saah AJ: Flow cytometric analysis of gamma delta T cells and natural killer cells in HIV-1 infection. Clin Immunol Immunopathol 1991;58:126-138.
8. 8. Lucia MB, Froio N, Tacconelli E, Tumbarello M, Rutella S, Rumi C, and Cauda R: CD16+CD56+CD8+ natural killer (NK) cells are decreased during HIV infection. Eur J Histochem 1997; 41(Suppl. 2):197-198.
9. 9. Dalgleish AG, Beverly PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984-1985;312:763-767.
10. 10. Rosemberg ZF and Fauci AS: Target cells in HIV infection. In: Fundamental Immunology (Paul WE, ed.). Raven Press, New York, 1993, pp 1378-1380.
11. 11. Gelderblom HR, Hausmann, EHS, Ozel M, Pauli G, and Koch MA: Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 1987;156: 171-176.
12. 12. Mann DL, Lasane F, Popovic M, Arthur LO, Robey WG, Blattner WA, and Newman MJ: HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol 1987;138:2640-2644.
13. 13. Mittler RS and Hoffmann MK: Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Science 1989;245:1380-1382.
14. 14. Wahl SM, Allen JB, Gartner S, et al.: HIV-1 and its envelope glycoprotein downregulate chemotactic ligand receptor and chemotactic function of peripheral blood monocytes. J Immunol 1989; 142:3553-3559.
15. 15. Oyaizu N, Chirmule N, Kalyanaraman VS, Hall WW, Good RA, and Pahwa S: Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci USA 1990;87:2379-2383.
16. 16. Krowka JF, Cuevas B, Maron DC, Stiemer KS, Asher MS, and Sheppard HW: Expression of CD69 after in vitro stimulation: A rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:95-104.
17. 17. Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, and Bolognesi DP: HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1989;142:3091-3097.
18. 18. Li CJ, Friedman DJ, Wang C, Metelev V, and Pardee AB: Induction of apoptosis in uninfected lymphocytes by HIV Tat protein. Science 1995;268:429-431.
19. 19. Zagury D: A naturally unbalanced combat. Nature Med 1997;3: 156-157.
20. 20. Barcova M, Kacani L, Speth C, and Dierich MP: gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-γ production. J Infect Dis 1998;177:905-913.
21. 21. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, and Pert CB: Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature (London) 1988;335:639-642.
22. 22. Dibbern DA, Glazner GW, Gozes I, Brenneman DE, and Hill JM: Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J Clin Invest 1997;99:2837-2841.
23. 23. West WH, Cannon GB, Kay HD, Bonnard GD, and Herberman RB: Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: Characterization of the effector cell. J Immunol 1977;118:355-361.
24. 24. Prussin C and Metcalfe DD: Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine anti-bodies. J Immunol Methods 1995;188:117-128.
25. 25. Oh SK, Cruikshank WW, Raina J, Blanchard GC, Adler WH, Walker J, and Kornfeld H: Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J Acquir Immune Defic Syndr 1992;5:251-256.
26. 26. Sirianni MC, Annibale B, Tagliaferri F, Fais S, De Luca S, Pallone F, Delle Fave G, and Aiuti F: Modulation of human natural killing activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Regul Pept 1992;38:79-87.
27. 27. Rola-Pleszczynski M, Bolduc D, and St-Pierre S: The effect of vasoactive intestinal peptide on human natural killer cell function. J Immunol 1985;135:2569-2573.
28. 28. Parks DR, Herzenberg LA, and Herzenberg LA: Flow cytometry and fluorescence activated cell sorting. In: Fundamental Immunology (Paul WE, ed.). Raven Press, New York, 1989, pp 781-783.
29. 29. Jewett A, Cavalcanti M, Giorgi J, and Bonavida B: Concomitant killing in vitro of both gp-120 coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J Immunol 1997;158:5492-5500.
30. 30. Sirianni MC, Tagliaferri F, and Aiuti F: Pathogenesis of natural killer cell deficiency in AIDS. Immunol Today 1990;11:81-82.
31. 31. Goicoa MA, Sen L, Iannitelli PS, Dies RA, and Estevez ME: Natural killer suppressor factor in sera from HIV-infected subjects. Scand J Immunol 1995;41:523-528.
32. 32. Ross ME and Caligiuri MA: Cytokine-induced apoptosis of human natural killer cells identifies as novel mechanism to regulate the innate immune response. Blood 1997;89:910-913.
33. 33. Azzari C, Rossi ME, Resti M, Caldini AL, Carbonella R, Ciappi S, and Vierucci A: VIP restores natural killer cell activity depressed by hepatitis B surface antigen. Viral Immunol 1992;5: 195-200.
34. 34. Ottaway CA, Lay TE, and Greenberg GR: High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. J Neuroimmunol 1990;29:149-155.